PD-1 inhibitor plus chemotherapy exhibits a better efficacy and equal tolerance compared with chemotherapy alone in advanced driver-gene-negative nonsquamous NSCLC patients. The gene discussed is PDCD1; the disease is non-small cell lung carcinoma.